Scripps Florida collaboration awarded $3.3 million to develop next-generation breast cancer therapies

(Scripps Research Institute) A pair of scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded up to $3.3 million from the National Cancer Institute of the National Institutes of Health (NIH) to create the next generation of breast cancer treatments for the thousands of patients whose current treatment options are limited.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news

Related Links:

ConclusionWithin an evolving context where services are centralised, new therapies emerge and subsequently come off patent, our understanding of the value of cancer therapies continues to evolve. This has important implications for the evaluation of new therapies and broader policy initiatives in this area.
Source: Irish Journal of Medical Science - Category: General Medicine Source Type: research
Authors: Kalimuthu S, Zhu L, Oh JM, Gangadaran P, Lee HW, Baek SH, Rajendran RL, Gopal A, Jeong SY, Lee SW, Lee J, Ahn BC Abstract Mesenchymal stem cells (MSCs) show therapeutic effects in various types of diseases. MSCs have been shown to migrate towards inflamed or cancerous tissues, and visualized after sacrificing the animal. MSCs are able to deliver drugs to target cells, and are an ideal candidate for cancer therapy. The purpose of this study was to track the migration of MSCs in tumor-bearing mice; MSCs were also used as drug delivery vehicles. Human breast cancer cells (MDA-MB-231) and anaplastic thyroid ca...
Source: International Journal of Medical Sciences - Category: Biomedical Science Tags: Int J Med Sci Source Type: research
Future Oncology, Ahead of Print.
Source: Future Oncology - Category: Cancer & Oncology Authors: Source Type: research
Future Oncology, Ahead of Print.
Source: Future Oncology - Category: Cancer & Oncology Authors: Source Type: research
Abstract Approximately half of all human cancers contain mutations in the TP53 tumor suppressor. In addition to mutations, there are single nucleotide polymorphisms (SNPs) in TP53 that can dampen p53 function, and can increase cancer risk and decrease the efficacy of cancer therapy. Approximately 6% of Africans and 1% of African-Americans express a p53 allele with a serine instead of proline at position 47 (Pro47Ser, or S47). The S47 variant is associated with increased breast cancer risk in pre-menopausal African Americans, and in a mouse model for the S47 variant, mice are predisposed to spontaneous cancers. We ...
Source: Cancer Biology and Therapy - Category: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research
Abstract Throughout various eras of breast cancer therapy, postmastectomy radiation therapy (PMRT) has played an important role in the treatment of locally advanced breast cancer. PMRT decreases locoregional recurrence and may improve overall survival in patients with tumors over 5 cm or positive lymph nodes. As novel cancer therapies improve survival in breast cancer, the role of radiation therapy is evolving. Individualized recommendations for PMRT dependent on pathologic response after neoadjuvant systemic therapy are under investigation. This review summarizes the role of PMRT during breast cancer therapy...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Surg Clin North Am Source Type: research
Publication date: Available online 7 July 2018Source: Journal of Molecular LiquidsAuthor(s): Samira Malekmohammadi, Hassan Hadadzadeh, Zahra AmirghofranAbstractThe purpose of this study is to develop a targeted drug delivery system containing folic acid-conjugated dendritic amino mesoporous silica nanoparticles (DFMSNs) loaded with a cyclometallated gold(III) complex, [Au(bzpy)Cl2] (bzpy = 2-benzylpyridine), as a cytotoxic agent (Au(drug)@DFMSNs). The products, including the Au(III) complex, DFMSNs, and Au(drug)@DFMSNs, were characterized by transmission electron microscopy (TEM), field-emission scanning electron micro...
Source: Journal of Molecular Liquids - Category: Molecular Biology Source Type: research
Work by theNanotechnology Characterization Laboratory (NCL), a joint initiative of NCI, NIST, and the FDA, has led to the discovery of a novel combination chemotherapy. This combination is shown to have synergistic effects on cytotoxicity to cancer cells in vitro, and to cause a substantial decrease in tumor growth in preclinical tumor models in vivo. Combination therapy using these agents may enhance the response rate of different cancers to these drugs and may significantly reduce side effects by permitting a lower therapeutic dose to be administered. SAIC Frederick'' s Nanotechnology Characterization   Laboratory&n...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Traditional chemotherapeutic drugs have shown limited clinical curative effects in antitumor therapy. The application of multidrug combination and adjuvant-drug carriers is a feasible strategy to overcome the limitations while minimizing the dosage of single drug and acquiring the synergistic effects in tumor therapy. However, the systemic toxicity, drug resistance, and tumor recurrence are still unavoidable. Here we develop core–shell nanoparticles (NPs) to encapsulate paclitaxel (PTX) and gemcitabine (GEM) for breast cancer therapy. We find that the NPs could encapsulate PTX and GEM, with an encapsulation efficienc...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Preclinical Reports Source Type: research
OrganometallicsDOI: 10.1021/acs.organomet.8b00354
Source: Organometallics - Category: Chemistry Authors: Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | International Medicine & Public Health | National Institutes of Health (NIH)